Umair Majeed

721 total citations · 1 hit paper
27 papers, 295 citations indexed

About

Umair Majeed is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Umair Majeed has authored 27 papers receiving a total of 295 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Umair Majeed's work include Cancer Immunotherapy and Biomarkers (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Lung Cancer Research Studies (5 papers). Umair Majeed is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Lung Cancer Research Studies (5 papers). Umair Majeed collaborates with scholars based in United States, Pakistan and Brazil. Umair Majeed's co-authors include Yanyan Lou, Rami Manochakian, Yujie Zhao, Karan Seegobin, Jason S. Starr, Muhamad Alhaj Moustafa, Pooja Advani, Tanios Bekaii‐Saab, Daniel H. Ahn and Hani M. Babiker and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Umair Majeed

22 papers receiving 291 citations

Hit Papers

Targeted therapy in advanced non-small cell lung cancer: ... 2021 2026 2022 2024 2021 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
    2021 177 citations Umair Majeed, Rami Manochakian et al. Journal of Hematology & Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Umair Majeed United States 5 159 149 95 81 34 27 295
Qiufan Zheng China 11 139 0.9× 189 1.3× 153 1.6× 111 1.4× 38 1.1× 38 353
Guzmán Alonso Spain 8 161 1.0× 177 1.2× 66 0.7× 75 0.9× 30 0.9× 34 313
Marco Brugia Italy 12 128 0.8× 218 1.5× 117 1.2× 100 1.2× 32 0.9× 31 354
Eisuke Kurihara Japan 8 113 0.7× 148 1.0× 110 1.2× 48 0.6× 32 0.9× 12 271
Chester Kao United States 8 160 1.0× 164 1.1× 110 1.2× 108 1.3× 28 0.8× 19 330
Scott Barker United States 6 175 1.1× 155 1.0× 57 0.6× 72 0.9× 23 0.7× 19 259
Carmen G. Rea Italy 7 143 0.9× 207 1.4× 92 1.0× 69 0.9× 34 1.0× 15 322
Giulia Grizzi Italy 12 185 1.2× 262 1.8× 82 0.9× 70 0.9× 30 0.9× 24 370
Janice J.N. Li Canada 9 219 1.4× 178 1.2× 114 1.2× 132 1.6× 30 0.9× 16 335
M. D’Arcangelo Italy 12 196 1.2× 200 1.3× 119 1.3× 79 1.0× 30 0.9× 31 360

Countries citing papers authored by Umair Majeed

Since Specialization
Citations

This map shows the geographic impact of Umair Majeed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Umair Majeed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Umair Majeed more than expected).

Fields of papers citing papers by Umair Majeed

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Umair Majeed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Umair Majeed. The network helps show where Umair Majeed may publish in the future.

Co-authorship network of co-authors of Umair Majeed

This figure shows the co-authorship network connecting the top 25 collaborators of Umair Majeed. A scholar is included among the top collaborators of Umair Majeed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Umair Majeed. Umair Majeed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Majeed, Umair, et al.. (2025). Advancements in Locoregional Therapies for Unresectable Intrahepatic Cholangiocarcinoma. Current Oncology. 32(2). 82–82. 1 indexed citations
2.
3.
Majeed, Umair, et al.. (2025). Unraveling trends and disparities in acute myocardial infarction-related mortality among adult cancer patients: A nationwide CDC-WONDER analysis (1999–2020). International Journal of Cardiology Cardiovascular Risk and Prevention. 24. 200371–200371. 2 indexed citations
4.
Garza‐Ramos, Cynthia De la, et al.. (2024). Ipilimumab and nivolumab plus radioembolization as salvage therapy for atezolizumab and bevacizumab refractory hepatocellular carcinoma resulting in complete pathologic response. SHILAP Revista de lepidopterología. 19(11). 5024–5028. 1 indexed citations
5.
Majeed, Umair, et al.. (2024). THE PREVALENCE OF ATRIAL FIBRILLATION CAUSES; A CROSS-SECTIONAL SURVEY AT A LARGE TEACHING HOSPITAL. Biological and Clinical Sciences Research Journal. 2024(1). 1 indexed citations
6.
Majeed, Umair, et al.. (2024). Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Clinical Trials. Clinical and Experimental Gastroenterology. Volume 17. 121–134. 1 indexed citations
7.
Iyer, Renuka, Nainesh Parikh, Richard D. Kim, et al.. (2023). A phase II study of atezolizumab (ATEZO) and bevacizumab (BEV) in combination with Y90 TARE in patients (pts) with hepatocellular carcinoma (HCC): Y90+/- BEAT.. Journal of Clinical Oncology. 41(4_suppl). TPS629–TPS629. 3 indexed citations
8.
9.
Majeed, Umair, et al.. (2023). Targeting leukemia inhibitory factor in pancreatic adenocarcinoma. Expert Opinion on Investigational Drugs. 32(5). 387–399. 2 indexed citations
10.
Garza‐Ramos, Cynthia De la, Seyed Ali Montazeri, Kaitlyn R. Musto, et al.. (2023). Outcomes of Radiation Segmentectomy for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease versus Chronic Viral Hepatitis. Journal of Hepatocellular Carcinoma. Volume 10. 987–996. 2 indexed citations
11.
Majeed, Umair, Karan Seegobin, Jason S. Lewis, et al.. (2023). Lung Cancer in Patients With Lynch Syndrome: Association or Coincidence?. Clinical Lung Cancer. 24(7). e237–e241. 1 indexed citations
12.
Ahn, Daniel H., Mohamad Bassam Sonbol, Tanios Bekaii‐Saab, et al.. (2023). Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail. World Journal of Clinical Oncology. 14(8). 285–296. 2 indexed citations
13.
Usón, Pedro Luiz Serrano, Heidi Kosiorek, Jun Yin, et al.. (2022). Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. Frontiers in Oncology. 11. 794009–794009. 12 indexed citations
14.
Seegobin, Karan, et al.. (2021). Macrophage Activation Led Acute Heart Failure Managed Successfully with Immunosuppression. Journal of Blood Medicine. Volume 12. 1037–1043. 3 indexed citations
15.
Majeed, Umair, et al.. (2021). Case Report: Alpelisib-Induced Drug Reaction With Eosinophilia and Systemic Symptoms: A Rare Manifestation of a Common Side Effect. Frontiers in Oncology. 11. 726785–726785. 4 indexed citations
16.
Seegobin, Karan, et al.. (2021). Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR. Frontiers in Oncology. 11. 750657–750657. 43 indexed citations
17.
Majeed, Umair, Rami Manochakian, Yujie Zhao, & Yanyan Lou. (2021). Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. Journal of Hematology & Oncology. 14(1). 108–108. 177 indexed citations breakdown →
18.
Majeed, Umair, et al.. (2021). Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer. Frontiers in Oncology. 11. 751209–751209. 16 indexed citations
19.
Parrondo, Ricardo, Umair Majeed, & Taimur Sher. (2020). Antibody‐based immunotherapy for treatment of immunoglobulin light‐chain amyloidosis. British Journal of Haematology. 191(5). 673–681. 3 indexed citations
20.
Seegobin, Karan, et al.. (2020). Factors affecting time to treatment in hepatocellular cancer.. Journal of Clinical Oncology. 38(15_suppl). e19088–e19088. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qiufan Zheng Breakdown of academic impact, for papers by Guzmán Alonso Breakdown of academic impact, for papers by Marco Brugia Breakdown of academic impact, for papers by Eisuke Kurihara Breakdown of academic impact, for papers by Chester Kao Breakdown of academic impact, for papers by Scott Barker Breakdown of academic impact, for papers by Carmen G. Rea Breakdown of academic impact, for papers by Giulia Grizzi Breakdown of academic impact, for papers by Janice J.N. Li Breakdown of academic impact, for papers by M. D’Arcangelo
Rankless by CCL
2026